Mast cells as therapeutic target in cancer

Domenico Ribatti

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Mast cells promote tumorigenesis and tumor progression, and have functions that favor the host. Increased mast cell number correlates with a poor prognosis in several human tumors. In different vascular tumors, as well as a number of hematological and solid tumors, mast cell accumulation correlate with increased neovascularization, tumor aggressiveness, and metastatic spread. Mast cells might act as a new target for the adjuvant treatment of tumors through the selective inhibition of angiogenesis, tissue remodeling and tumor-promoting molecules, permitting the secretion of cytotoxic cytokines and preventing mast cell-mediated immune suppression.

Original languageEnglish
JournalEuropean Journal of Pharmacology
DOIs
Publication statusAccepted/In press - Sep 4 2014

Fingerprint

Mast Cells
Neoplasms
Therapeutics
Blood Vessels
Carcinogenesis
Cell Count
Cytokines

Keywords

  • Anticancer agents
  • Mast cells
  • Tryptase
  • Tumor growth
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Mast cells as therapeutic target in cancer. / Ribatti, Domenico.

In: European Journal of Pharmacology, 04.09.2014.

Research output: Contribution to journalArticle

@article{a3bf0fafec044e4e9acc2d7d9060631f,
title = "Mast cells as therapeutic target in cancer",
abstract = "Mast cells promote tumorigenesis and tumor progression, and have functions that favor the host. Increased mast cell number correlates with a poor prognosis in several human tumors. In different vascular tumors, as well as a number of hematological and solid tumors, mast cell accumulation correlate with increased neovascularization, tumor aggressiveness, and metastatic spread. Mast cells might act as a new target for the adjuvant treatment of tumors through the selective inhibition of angiogenesis, tissue remodeling and tumor-promoting molecules, permitting the secretion of cytotoxic cytokines and preventing mast cell-mediated immune suppression.",
keywords = "Anticancer agents, Mast cells, Tryptase, Tumor growth, Tyrosine kinase inhibitors",
author = "Domenico Ribatti",
year = "2014",
month = "9",
day = "4",
doi = "10.1016/j.ejphar.2015.02.056",
language = "English",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Mast cells as therapeutic target in cancer

AU - Ribatti, Domenico

PY - 2014/9/4

Y1 - 2014/9/4

N2 - Mast cells promote tumorigenesis and tumor progression, and have functions that favor the host. Increased mast cell number correlates with a poor prognosis in several human tumors. In different vascular tumors, as well as a number of hematological and solid tumors, mast cell accumulation correlate with increased neovascularization, tumor aggressiveness, and metastatic spread. Mast cells might act as a new target for the adjuvant treatment of tumors through the selective inhibition of angiogenesis, tissue remodeling and tumor-promoting molecules, permitting the secretion of cytotoxic cytokines and preventing mast cell-mediated immune suppression.

AB - Mast cells promote tumorigenesis and tumor progression, and have functions that favor the host. Increased mast cell number correlates with a poor prognosis in several human tumors. In different vascular tumors, as well as a number of hematological and solid tumors, mast cell accumulation correlate with increased neovascularization, tumor aggressiveness, and metastatic spread. Mast cells might act as a new target for the adjuvant treatment of tumors through the selective inhibition of angiogenesis, tissue remodeling and tumor-promoting molecules, permitting the secretion of cytotoxic cytokines and preventing mast cell-mediated immune suppression.

KW - Anticancer agents

KW - Mast cells

KW - Tryptase

KW - Tumor growth

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84928957873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928957873&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2015.02.056

DO - 10.1016/j.ejphar.2015.02.056

M3 - Article

AN - SCOPUS:84928957873

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -